Guggenheim analyst Brad Canino reiterated a Buy rating and $38.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments